surpass cvot tirzepatide results Efficacy and safety of in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Reduction of prevalence of patients

GLP-1RA for the treatment of pediatric MASLD MASLD is highly prevalent in children and adolescents, with an estimated overall global prevalence of 7.4%, rising to 52.49% in the context of obesity

27 The first trial had participants who were not on PAP therapy at baseline, while participants who were on PAP at baseline were placed in the second trial

Once removed from refrigeration, tirzepatide pens remain stable at room temperature for 28 days, making travel convenient and practical

The neuroinflammatory and CGRP changes may resolve more slowly than the metabolic changes, providing a window of continued benefit

Not necessarily, but the odds are against maintaining full weight loss without intervention

While both drugs leverage the bodys natural hormone-based regulation of energy homeostasis, it is crucial to distinguish these two therapies